Cargando…
Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma
BACKGROUND: Inhibition of the sonic hedgehog (SHH) pathway with Smoothened (SMO) inhibitors is a promising treatment strategy in SHH-activated medulloblastoma, especially in adult patients. However, the problem is that tumors frequently acquire resistance to the treatment. To understand the underlyi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034118/ https://www.ncbi.nlm.nih.gov/pubmed/35475274 http://dx.doi.org/10.1093/noajnl/vdac026 |
_version_ | 1784693045864693760 |
---|---|
author | Krausert, Sonja Brabetz, Sebastian Mack, Norman L Schmitt-Hoffner, Felix Schwalm, Benjamin Peterziel, Heike Mangang, Aileen Holland-Letz, Tim Sieber, Laura Korshunov, Andrey Oehme, Ina Jäger, Natalie Witt, Olaf Pfister, Stefan M Kool, Marcel |
author_facet | Krausert, Sonja Brabetz, Sebastian Mack, Norman L Schmitt-Hoffner, Felix Schwalm, Benjamin Peterziel, Heike Mangang, Aileen Holland-Letz, Tim Sieber, Laura Korshunov, Andrey Oehme, Ina Jäger, Natalie Witt, Olaf Pfister, Stefan M Kool, Marcel |
author_sort | Krausert, Sonja |
collection | PubMed |
description | BACKGROUND: Inhibition of the sonic hedgehog (SHH) pathway with Smoothened (SMO) inhibitors is a promising treatment strategy in SHH-activated medulloblastoma, especially in adult patients. However, the problem is that tumors frequently acquire resistance to the treatment. To understand the underlying resistance mechanisms and to find ways to overcome the resistance, preclinical models that became resistant to SMO inhibition are needed. METHODS: To induce SMO inhibitor resistant tumors, we have treated a patient-derived xenograft (PDX) model of SHH medulloblastoma, sensitive to SMO inhibition, with 20 mg/kg Sonidegib using an intermitted treatment schedule. Vehicle-treated and resistant models were subjected to whole-genome and RNA sequencing for molecular characterization and target engagement. In vitro drug screens (76 drugs) were performed using Sonidegib-sensitive and -resistant lines to find other drugs to target the resistant lines. One of the top hits was then validated in vivo. RESULTS: Nine independent Sonidegib-resistant PDX lines were generated. Molecular characterization of the resistant models showed that eight models developed missense mutations in SMO and one gained an inactivating point mutation in MEGF8, which acts downstream of SMO as a repressor in the SHH pathway. The in vitro drug screen with Sonidegib-sensitive and -resistant lines identified good efficacy for Selinexor in the resistant line. Indeed, in vivo treatment with Selinexor revealed that it is more effective in resistant than in sensitive models. CONCLUSIONS: We report the first human SMO inhibitor resistant medulloblastoma PDX models, which can be used for further preclinical experiments to develop the best strategies to overcome the resistance to SMO inhibitors in patients. |
format | Online Article Text |
id | pubmed-9034118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-90341182022-04-25 Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma Krausert, Sonja Brabetz, Sebastian Mack, Norman L Schmitt-Hoffner, Felix Schwalm, Benjamin Peterziel, Heike Mangang, Aileen Holland-Letz, Tim Sieber, Laura Korshunov, Andrey Oehme, Ina Jäger, Natalie Witt, Olaf Pfister, Stefan M Kool, Marcel Neurooncol Adv Basic and Translational Investigations BACKGROUND: Inhibition of the sonic hedgehog (SHH) pathway with Smoothened (SMO) inhibitors is a promising treatment strategy in SHH-activated medulloblastoma, especially in adult patients. However, the problem is that tumors frequently acquire resistance to the treatment. To understand the underlying resistance mechanisms and to find ways to overcome the resistance, preclinical models that became resistant to SMO inhibition are needed. METHODS: To induce SMO inhibitor resistant tumors, we have treated a patient-derived xenograft (PDX) model of SHH medulloblastoma, sensitive to SMO inhibition, with 20 mg/kg Sonidegib using an intermitted treatment schedule. Vehicle-treated and resistant models were subjected to whole-genome and RNA sequencing for molecular characterization and target engagement. In vitro drug screens (76 drugs) were performed using Sonidegib-sensitive and -resistant lines to find other drugs to target the resistant lines. One of the top hits was then validated in vivo. RESULTS: Nine independent Sonidegib-resistant PDX lines were generated. Molecular characterization of the resistant models showed that eight models developed missense mutations in SMO and one gained an inactivating point mutation in MEGF8, which acts downstream of SMO as a repressor in the SHH pathway. The in vitro drug screen with Sonidegib-sensitive and -resistant lines identified good efficacy for Selinexor in the resistant line. Indeed, in vivo treatment with Selinexor revealed that it is more effective in resistant than in sensitive models. CONCLUSIONS: We report the first human SMO inhibitor resistant medulloblastoma PDX models, which can be used for further preclinical experiments to develop the best strategies to overcome the resistance to SMO inhibitors in patients. Oxford University Press 2022-03-13 /pmc/articles/PMC9034118/ /pubmed/35475274 http://dx.doi.org/10.1093/noajnl/vdac026 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Basic and Translational Investigations Krausert, Sonja Brabetz, Sebastian Mack, Norman L Schmitt-Hoffner, Felix Schwalm, Benjamin Peterziel, Heike Mangang, Aileen Holland-Letz, Tim Sieber, Laura Korshunov, Andrey Oehme, Ina Jäger, Natalie Witt, Olaf Pfister, Stefan M Kool, Marcel Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma |
title | Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma |
title_full | Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma |
title_fullStr | Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma |
title_full_unstemmed | Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma |
title_short | Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma |
title_sort | predictive modeling of resistance to smo inhibition in a patient-derived orthotopic xenograft model of shh medulloblastoma |
topic | Basic and Translational Investigations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034118/ https://www.ncbi.nlm.nih.gov/pubmed/35475274 http://dx.doi.org/10.1093/noajnl/vdac026 |
work_keys_str_mv | AT krausertsonja predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT brabetzsebastian predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT macknormanl predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT schmitthoffnerfelix predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT schwalmbenjamin predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT peterzielheike predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT mangangaileen predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT hollandletztim predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT sieberlaura predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT korshunovandrey predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT oehmeina predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT jagernatalie predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT wittolaf predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT pfisterstefanm predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma AT koolmarcel predictivemodelingofresistancetosmoinhibitioninapatientderivedorthotopicxenograftmodelofshhmedulloblastoma |